{"title":"The Effect of Low-Density Lipoprotein Receptor-Related Protein-1 on Acute Kidney Injury and Renal Tubular Epithelial Triglyceride Accumulation.","authors":"Weiteng Wang, Jieyi Luo, Yingwen Chen, Huaban Liang, Zhilian Li, Yuanhan Chen, Jintao He, Xinling Liang","doi":"10.1159/000545851","DOIUrl":"10.1159/000545851","url":null,"abstract":"<p><strong>Introduction: </strong>Various types of acute kidney injury (AKI) are associated with triglyceride (TG) accumulation in renal tubular epithelial cells, but the role and mechanisms of TG accumulation in AKI remain unclear. This study aimed to explore the impact of low-density lipoprotein (LDL) receptor-related protein-1 (LRP1), a protein that mediates TG endocytosis, on ischemia-reperfusion injury (IRI)-induced AKI and TG accumulation in renal tubular epithelial cells.</p><p><strong>Methods: </strong>We established an IRI-induced AKI mouse model and assessed LRP1 expression by Western blot, RT-qPCR, and immunofluorescence. The LRP1 antagonist receptor-associated protein (RAP) was used to evaluate the effect of LRP1 on AKI and renal TG accumulation in the AKI mouse model. We applied a carbonyl cyanide 3-chlorophenylhydrazone (CCCP)-induced hypoxia-reoxygenation model to HK-2 cells in vitro. The effects of very low-density lipoproteins (VLDLs) and LRP1 silencing on TG levels, cell viability, and apoptosis in HK-2 cells were observed.</p><p><strong>Results: </strong>We observed significant TG accumulation in renal tissue during IRI-AKI, accompanied by upregulation of LRP1 in renal tubular epithelial cells. After intervention with the LRP1 antagonist RAP, AKI was significantly alleviated, and TG levels in renal tissue were notably reduced. However, in the in vitro model, although VLDL increased TG levels in HK-2 cells in both normal culture and hypoxia-reoxygenation conditions, it did not alleviate the decrease in cell viability induced by CCCP. In the absence of exogenous VLDL, silencing LRP1 still reduced CCCP-induced TG accumulation and cell apoptosis, although the reduction in TG levels was less pronounced compared to the presence of exogenous VLDL.</p><p><strong>Conclusion: </strong>Our study demonstrated that the increased expression of LRP1 on renal tubular epithelial cells contributes to IRI-induced AKI and TG accumulation. The injury effects of LRP1 on the renal tubules are independent of TG endocytosis. Targeting the inhibition of LRP1 may emerge as a novel therapeutic strategy for AKI.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"320-331"},"PeriodicalIF":3.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12112978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2025-04-14eCollection Date: 2025-01-01DOI: 10.1159/000545604
Junlan Yang, Zhiyuan Wei, Haifeng Ni, Qianqian Wu, Siqi Peng, Wen Shi, Xiaoxu Wang, Yan Yang, Jianan Jiang, Jingyuan Cao, Yao Wang, Liyuan Zhang, Aihua Zhang, Xiaoliang Zhang, Bin Wang
{"title":"Urinary Myeloid Bodies as a Biomarker for Early Diagnosis and Monitoring of Enzyme Replacement Therapy in Fabry Disease.","authors":"Junlan Yang, Zhiyuan Wei, Haifeng Ni, Qianqian Wu, Siqi Peng, Wen Shi, Xiaoxu Wang, Yan Yang, Jianan Jiang, Jingyuan Cao, Yao Wang, Liyuan Zhang, Aihua Zhang, Xiaoliang Zhang, Bin Wang","doi":"10.1159/000545604","DOIUrl":"10.1159/000545604","url":null,"abstract":"<p><strong>Introduction: </strong>The prevalence of urinary myeloid bodies in Fabry disease patients and their correlation with renal involvement remains unclear.</p><p><strong>Methods: </strong>This single-center, retrospective study included 25 patients with Fabry disease and 27 controls. We analyzed 24-h urine samples for the presence of urinary myeloid bodies and evaluated clinical data, including serum creatinine, estimated glomerular filtration rate (eGFR), 24-h urinary protein levels, α-Gal A, and Lyso-GL-3. Seven Fabry patients underwent analysis of urine samples before and after 1 year of enzyme replacement therapy (ERT).</p><p><strong>Results: </strong>Urinary myeloid bodies were detected in 84% of Fabry patients (21 out of 25), with no significant gender differences. None of the healthy controls or patients with other renal disease patients had urinary myeloid bodies. Among the Fabry patients with myeloid bodies, 48% had no proteinuria, and 52% were in CKD1 stage G1. Furthermore, urinary myeloid bodies were detected in 4 patients under the age of 20, despite the absence of or only minimal proteinuria, and these patients all exhibited a substantial number of myeloid bodies. After 1 year of ERT, significant reductions in both the count (<i>p</i> = 0.043) and area ratio (<i>p</i> = 0.028) of myeloid bodies were observed.</p><p><strong>Conclusion: </strong>Urinary myeloid bodies are specific to Fabry disease and are associated with early renal injury, even in the absence of proteinuria. These findings suggest that urinary myeloid bodies may serve as a noninvasive biomarker for the early diagnosis of Fabry disease and for monitoring the efficacy of ERT.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"332-341"},"PeriodicalIF":3.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2025-04-07eCollection Date: 2025-01-01DOI: 10.1159/000545240
Yufei Sun, Shuang Liu, Wan Ding, Chun Zhu, Gengru Jiang, Huilin Li
{"title":"Recent Advances in miRNA Biomarkers for Diagnosis and Prognosis of Focal Segmental Glomerulosclerosis.","authors":"Yufei Sun, Shuang Liu, Wan Ding, Chun Zhu, Gengru Jiang, Huilin Li","doi":"10.1159/000545240","DOIUrl":"10.1159/000545240","url":null,"abstract":"<p><strong>Background: </strong>Focal segmental glomerulosclerosis (FSGS) is an increasingly prevalent group of refractory glomerular diseases and a significant aetiology of end-stage renal disease. Podocyte injury and depletion significantly contribute to the pathogenesis and progression of FSGS. MicroRNAs (miRNAs) are noncoding RNAs that regulate the expression of specific genes in relevant cells, thereby playing crucial roles in the pathogenesis of FSGS. Many studies have shown that miRNAs can be secreted from cells into body fluids and that these miRNAs in the circulation are highly stable. The gold standard for FSGS diagnosis is kidney biopsy; however, the clinical heterogeneity of FSGS, along with variations in histology and nonspecific morphological features, can impact its diagnostic accuracy. Thus, the discovery of novel and efficacious biomarkers is crucial in facilitating the diagnosis of FSGS. In addition, the degree of kidney damage in patients with FSGS varies at different stages, necessitating individualized diagnosis and treatment approaches. Considering the side effects of glucocorticoids, determining whether a patient is steroid resistant is vital. Thus, ideal biomarkers should not only be specific and sensitive but also have the ability to accurately reflect the stage or prognosis of the disease to improve the treatment for patients.</p><p><strong>Summary: </strong>To date, numerous studies have shown that both urinary miRNAs and plasma miRNAs are potential biomarkers for FSGS. In addition, the identification of miRNA biomarkers specific for the FSGS disease state may provide new insights into the underlying pathological mechanism of FSGS.</p><p><strong>Key messages: </strong>Here we summarize the currently available miRNA biomarkers that could help us better understand the diagnosis, disease activity, prognosis, and clinical features of FSGS.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"283-291"},"PeriodicalIF":3.2,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2025-04-06eCollection Date: 2025-01-01DOI: 10.1159/000545663
Fei Liu, Xiaoyi Li, Qiuyu Li, Jinglan Gu, Qi Shi, Jiayi Song, Na Jiao, Jianhua Mao
{"title":"Deciphering Intercellular Communication of the Immune Landscape within Autosomal Dominant Polycystic Kidney Disease Microenvironment at Single-Cell Resolution.","authors":"Fei Liu, Xiaoyi Li, Qiuyu Li, Jinglan Gu, Qi Shi, Jiayi Song, Na Jiao, Jianhua Mao","doi":"10.1159/000545663","DOIUrl":"10.1159/000545663","url":null,"abstract":"<p><strong>Introduction: </strong>Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder that often leads to end-stage renal disease, with disease progression deeply influenced by the renal microenvironment. This study aims to unravel the critical cellular types and their intricate interactions within the ADPKD microenvironment.</p><p><strong>Methods: </strong>Leveraging single-cell transcriptome data from seven ADPKD and three healthy human kidney samples, we systematically dissected the cellular landscape of the ADPKD microenvironment. Our approach included CellChat for cell-cell communication analysis, VISION for pathway enrichment analysis, pySCENIC for regulon activity calculation, and Monocle V3 for pseudotime trajectory construction.</p><p><strong>Results: </strong>We identified nine major cell lineages, with a notable increase of mononuclear phagocytes (MNPs), T cells, and fibroblasts in the ADPKD microenvironment. These cells collectively orchestrated a distinctive microenvironment, marked by complex intercellular networks. Notably, a specific subset of macrophages exhibited an \"M2-like\" phenotype, which was driven by IL-10 signaling from M1-like macrophages and contributed to cyst cell proliferation. Immunosuppression was predominantly mediated by CD4+ T cells, activated by macrophages through immune checkpoint pathways, such as PDL1 signaling. The fibrotic expansion was a cumulative effect of fibroblast activation and proliferation, modulated by macrophages and cyst-lining epithelial cells.</p><p><strong>Conclusion: </strong>This comprehensive investigation provides valuable insights into the diverse landscapes of the ADPKD microenvironment at single-cell resolution, emphasizing MNPs, T cells, and fibroblasts. The study unveils complex interactions among these cell types, shedding light on an understanding of the immunological aspect of ADPKD and proposing potential therapeutic targets.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"302-318"},"PeriodicalIF":3.2,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2025-04-04eCollection Date: 2025-01-01DOI: 10.1159/000545008
Lanbo Teng, Huanan Li, Yingying Han, Tao Yuan, Chuhan Xu, Tao Tan, Wenxiu Chang
{"title":"Association between Restless Legs Syndrome and Sleep Disturbance and 3-Year Mortality in Hemodialysis Patients.","authors":"Lanbo Teng, Huanan Li, Yingying Han, Tao Yuan, Chuhan Xu, Tao Tan, Wenxiu Chang","doi":"10.1159/000545008","DOIUrl":"10.1159/000545008","url":null,"abstract":"<p><strong>Introduction: </strong>Whether restless legs syndrome (RLS) and sleep disturbance (SD) in hemodialysis (HD) patients influence all-cause and cardiovascular mortality remains controversial. The aim of this study was to evaluate the association between RLS or SD and 3-year mortality in HD patients.</p><p><strong>Methods: </strong>A total of 301 patients who underwent HD were examined in April 2021 and were followed up for 3 years. The median follow-up time was 36.0 [33.3, 36.0] months. Fifty-four patients fulfilled the diagnosis of RLS (17.9%), 126 patients complained of SD (41.9%). Demographic parameters, clinical features, laboratory indices, and two questionnaires to assess the diagnosis of RLS and sleep status were collected. All-cause mortality and cardiovascular mortality in this population were evaluated. Cox regression analyses and Kaplan-Meier curves were performed to determine the effect of RLS or SD on 3-year mortality.</p><p><strong>Results: </strong>The RLS group reported that 29 patients (53.8%) exhibited concurrent symptoms of SD. The presence of RLS or SD alone did not significantly elevate the risk of all-cause mortality (<i>p</i> = 0.053 and <i>p</i> = 0.193). However, the coexistence of RLS and SD was identified as an independent risk factor for all-cause mortality (<i>p</i> = 0.011). Furthermore, the various combinations associated with RLS or SD were found to be independently correlated with the risk of cardiovascular death (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The combination of RLS and SD in HD patients is associated with an increased risk of cardiovascular and all-cause mortality, underscoring the clinical significance of this association.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"160-169"},"PeriodicalIF":3.2,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kidney DiseasesPub Date : 2025-04-04eCollection Date: 2025-01-01DOI: 10.1159/000545727
Ai-Hui Li, Yang Li, Meng-Shi Li, Zhuo-Ran Song, Ji-Cheng Lv, Hong Zhang, Xiao-Juan Yu, Xu-Jie Zhou
{"title":"Repeated Kidney Biopsy in Membranoproliferative Glomerulonephritis.","authors":"Ai-Hui Li, Yang Li, Meng-Shi Li, Zhuo-Ran Song, Ji-Cheng Lv, Hong Zhang, Xiao-Juan Yu, Xu-Jie Zhou","doi":"10.1159/000545727","DOIUrl":"https://doi.org/10.1159/000545727","url":null,"abstract":"<p><strong>Introduction: </strong>Membranoproliferative glomerulonephritis (MPGN) is a heterogeneous pattern of glomerular injury. Repeated kidney biopsies may elucidate pathogenic mechanisms and guide diagnostic strategies.</p><p><strong>Methods: </strong>We included 82 patients diagnosed with MPGN by kidney biopsy who underwent at least two biopsies between 1997 and 2023 at Peking University First Hospital. Clinical and pathological data were analyzed retrospectively.</p><p><strong>Results: </strong>Of 342 MPGN patients, 95 (28%) had repeated biopsies (0.9-4.0 years apart). This incidence was higher than in other glomerulonephropathies under immunosuppression. Among the 82 patients analyzed (excluding kidney transplants and ≤3-month biopsy intervals), 42 were initially diagnosed with non-MPGN pathology. At the second biopsy, proteinuria increased (from 2.9 to 6.3 g/day), eGFR declined (from 76 to 47 mL/min/1.73 m<sup>2</sup>), and renal C3 deposition was stronger (<i>p</i> = 0.04). Thirty patients (37%) had etiological reclassification, mostly to monoclonal gammopathy of renal significance (MGRS). Compared to idiopathic MPGN, MGRS patients were older (53 vs. 35 years) and had worse renal function (eGFR 57 vs. 81 mL/min/1.73 m<sup>2</sup>) but slower eGFR decline (-7 vs. -12 mL/min/1.73 m<sup>2</sup>/year). Most MGRS patients (64%) remained negative for monoclonal protein in serum or urine immunofixation, necessitating repeat biopsy and clone-directed therapy.</p><p><strong>Conclusion: </strong>In this study, about half and one-third of patients underwent morphological and etiological reclassification, respectively. Stronger complement deposition may drive morphological changes. Repeated kidney biopsies are crucial for diagnosing MGRS, especially in patients with negative immunofixation.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"258-269"},"PeriodicalIF":3.2,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Increasing Prescription of SGLT2 Inhibitors with Expanded Indications to the Elderly Population in Japan.","authors":"Yasuhiro Oda, Hiroshi Nishi, Mariko Sekiguchi, Motoki Odawara, Masaomi Nangaku","doi":"10.1159/000545626","DOIUrl":"10.1159/000545626","url":null,"abstract":"<p><strong>Introduction: </strong>Indications for sodium-glucose cotransporter-2 (SGLT2) inhibitors have expanded to include heart failure and chronic kidney disease after the year 2020. Whether and how the demographic trends in the prescription of SGLT2 inhibitors have changed after the expansion of indications have not been studied extensively.</p><p><strong>Methods: </strong>This study is a descriptive analysis of serial, cross-sectional data on nationwide prescription of SGLT2 inhibitors between April 2016 and March 2023 obtained from NDB Open Data Japan, which contains more than 95% of total health insurance reimbursement claims in the nation.</p><p><strong>Results: </strong>The total number of SGLT2 inhibitor tablets prescribed in outpatient settings with prescriptions papers increased from 577,996,158 tablets in fiscal year (FY) 2020 to 904,598,175 tablets in FY 2022. Patients aged 75 years and older accounted for 20.3% of the total prescriptions in FY 2020, and this proportion increased to 27.8% in FY 2022. Among all SGLT2 inhibitors, the tablet that expanded its indications for patients with heart failure and chronic kidney disease the earliest showed the largest percentage increase in the number of prescribed tablets during this period and the highest share of the elderly population in its recipients in both sexes (men, 35.9%; women, 49.4%) in FY 2022. The number of prescribed SGLT2 inhibitor tablets per population was constantly higher in men than in women between FY 2020 and 2022, which is consistent with the sex difference in the prevalence of these diseases.</p><p><strong>Conclusion: </strong>Prescription of SGLT2 inhibitors to the elderly population is no longer infrequent and accounts for a large portion of the entire prescription of SGLT2 inhibitors in Japan. These findings contribute to updating our perception on the demographics of SGLT2 inhibitor recipients.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"292-301"},"PeriodicalIF":3.2,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic Insights into Urinary Stone Formation: Evidence from Mendelian Randomization, Clinical, and in vivo Studies.","authors":"Lintao Miao, Jiacheng Xiang, Yuanyuan Yang, Senyuan Hong, Jianxuan Sun, Sihan Zhang, Yuan Gong, Qidong Xia, Shaogang Wang","doi":"10.1159/000545550","DOIUrl":"https://doi.org/10.1159/000545550","url":null,"abstract":"<p><strong>Introduction: </strong>The global rise in urinary stone prevalence has become a significant health and economic challenge. Linked to metabolic disorders such as obesity and diabetes, urinary stones represent a complex systemic condition that requires a comprehensive understanding of metabolic profiles for effective management.</p><p><strong>Methods: </strong>The methodological quality of this study was evaluated in accordance with the STROBE-MR checklist. Using genome-wide association study (GWAS) data for 1,091 blood and 1,172 urine metabolites, we conducted a two-sample Mendelian randomization (MR) analysis, validated by meta-analysis, to explore metabolic influences on stone formation. Multivariable and mediation MR analyses were performed to identify independent metabolite influences and their interaction with gut microbiota and metabolism-related genes. Clinical metabolomic analysis and further animal experiments substantiated our findings.</p><p><strong>Results: </strong>Univariable MR identified 119 blood and 63 urine metabolites associated with urinary stones, with 16 blood and 2 urine metabolites showing robust associations post-correction. Notably, mannose and 3-aminoisobutyrate emerged as independent influencers of stone formation. Mediation MR suggested these metabolites as potential mediators in the gut microbiota's influence on stone formation. Clinical urine sample analysis indicates higher mannose levels in normal renal sides than stone sides. Animal studies confirmed mannose's protective role by reducing renal calcium oxalate crystal deposition.</p><p><strong>Conclusion: </strong>Our study establishes causal links between specific metabolites and urinary stones, shedding light on the intricate biological mechanisms of stone formation. The discovery of mannose as a protective factor opens avenues for future research and clinical applications, offering promising directions for the prevention and treatment of stones.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"240-257"},"PeriodicalIF":3.2,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}